

Nizoral

TRADEMARK

(ketoconazole)

tablets

over 5 million prescriptions world-wide.

Oral medication in antifungal therapy:



Doctors and patients around the world are discovering the modern simplicity of Nizoral oral therapy. Common but often problematic fungal infections can now be treated effectively and elegantly.

Typically, in *Candida* vaginitis, 2 oral tablets once daily for 5 days is all it takes today to effectively cure the problem.




**JANSSEN
PHARMACEUTICA**

the drug discovery company

Prescribing information

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and GI-tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed. **Side-effects, precautions, contra-indications:** contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂-blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Ketoconazole 200 mg once daily produces a transient decrease in plasma levels of testosterone. During long-term therapy at this dose, testosterone levels are usually not significantly different from controls. In rare instances, gynecomastia has been reported.



MSTTM SOONER RATHER THAN LATER
Morphine Sulphate B.P. Continus[®] Tablets

For full prescribing information see overleaf.

MST

Continus® Tablets

Morphine Sulphate BP

Presentation MST Continus tablets are film-coated, bi-convex and contain Morphine Sulphate B.P. incorporated within the patented controlled release system. The tablets are available in four strengths: 10mg (golden brown), 30mg (dark purple), 60mg (orange), 100mg (grey).

Uses MST Continus tablets are indicated for the prolonged relief of severe pain. **Dosage and Administration** MST Continus tablets must be swallowed whole and not chewed. MST Continus tablets should be used twice daily, at 12 hourly intervals. The dosage is dependent upon the severity of the pain and the patient's previous history of analgesic requirements. A patient presenting with severe pain should normally be started on a dosage of one or two MST Continus tablets 10mg twice daily. Increasing severity of pain or tolerance to morphine will require increased dosage of MST Continus tablets using 10mg, 30mg, 60mg and 100mg tablets alone or in combination to achieve the desired relief. A patient transferred from other oral morphine preparations should normally receive the same total twenty-four hour morphine dosage divided between morning and evening administration. Patients receiving MST Continus tablets in place of parenteral morphine should be given a sufficiently increased dosage to compensate for any reduction in analgesic effects associated with oral administration. Usually such increased requirement is of the order of 50% to 100%. In such patients individual dose adjustments are required. **Post-operative Pain** MST Continus tablets are not recommended in the first 24 hours post-operatively; thereafter it is suggested that the following dosage schedule be observed at the physician's discretion:— (a) MST Continus tablets 20mg 12 hourly to patients under 70 kilograms. (b) MST Continus tablets 30mg 12 hourly to patients over 70 kilograms. Supplemental parenteral morphine may be given if required but with careful attention to the total dosage of morphine, and bearing in mind the prolonged effects of morphine in the MST Continus formulation. As with all oral morphine preparations, MST Continus tablets should be used with caution post-operatively, and particularly in "acute abdomen" and following abdominal surgery. **Contra-Indications, Warnings, etc.** Respiratory depression, obstructive airways disease, known morphine sensitivity, acute hepatic disease, concurrent administration of monoamine oxidase inhibitors or within two weeks of discontinuation of their use. MST Continus tablets are not recommended for paediatric use or in pregnancy. Pre-operative administration of MST Continus tablets is not recommended and is not an approved indication. **Precautions** As with all narcotics a reduction in dosage may be advisable in the elderly, in hypothyroidism, in renal and chronic hepatic disease. **Warnings and Adverse Effects** MST Continus tablets should not be used where there is a possibility of paralytic ileus occurring. Should paralytic ileus be suspected or occur during use, MST Continus tablets should be discontinued immediately. As with all morphine preparations, patients who are to undergo cordotomy or other pain relieving surgical procedures should not receive MST Continus tablets for 24 hours prior to surgery. If further treatment with MST Continus tablets is then indicated the dosage should be adjusted to the new post-operative requirement. Tolerance and dependence may occur. When nausea and vomiting are troublesome, MST Continus tablets can be readily combined with phenothiazine antiemetics. It should be noted however, that morphine potentiates the effects of tranquillisers, anaesthetics, hypnotics and sedatives. As with all morphine preparations, constipation may occur, which may be treated with appropriate laxatives. **Overdosage** Signs of morphine toxicity and overdosage: These are likely to consist of pin-point pupils, respiratory depression and hypotension. Circulatory failure and deepening coma may occur in more severe cases. Treatment of morphine overdosage: Administer naloxone 0.4mg intravenously. Repeat at 2-3 minute intervals as necessary, or by an infusion of 2mg in 500ml of normal saline or 5% dextrose (0.004 mg/ml). The infusion should be run at a rate related to the previous bolus doses administered and should be in accordance with the patient's response. Empty the stomach. A 0.02% aqueous solution of potassium permanganate may be used for lavage. Assist respiration if necessary. Maintain fluid and electrolyte levels. In the case of MST Continus tablets, the physician should be aware that tablets remaining in the intestine will continue to release morphine sulphate for a period of hours. **Pharmaceutical Precautions** MST Continus tablets should be stored in a cool, dry place protected from light. **Legal Category** POM/MDA **Package Quantities** Blister packs of 60 tablets. **Further Information** Morphine Sulphate B.P. is readily absorbed from the gastrointestinal tract following oral administration. The patented controlled release system maintains plasma levels of morphine over a period of up to twelve hours and reduces the likelihood of morphine associated side-effects. **Basic NHS Cost** (per pack of 60 tablets) 10 mg £7.70 PL 0337/0055 30mg £18.49 PL 0337/0059 60mg £36.06 PL 0337/0087 100mg £57.10 PL 0337/0088

© MST Continus is a Registered Trade Mark
© Napp Laboratories 1986
Napp Laboratories, The Science Park
Cambridge CB4 4GW
Member of Napp
Pharmaceutical Group

NAPP

ABC OF SEXUALLY TRANSMITTED DISEASES

MICHAEL W ADLER


AIDS and genital herpes are only the more dramatic signs of a general increase in the number and range of sexually transmitted diseases. Yet these conditions are not seen only in sexually transmitted disease clinics and doctors need to be aware that common clinical problems such as urinary tract infections, rashes, and pelvic pain may have a sexual origin. Professor Michael Adler's ABC describes the presentation, diagnosis, and management of these conditions, emphasising the need to take a broad clinical view of patients and their problems.

Price: Inland £4.00; Overseas £6.00/USA\$10.50
(BMA members: Inland £3.50; Overseas £5.50/USA\$9.50)
Despatched by air overseas


Payment must be enclosed with order

Order your copy now

From: The Publisher, British Medical Journal,
BMA House, Tavistock Square, London WC1H 9JR
or any leading bookseller



Selection of books from the BMJ. . .



ABC OF PLASTIC AND RECONSTRUCTIVE SURGERY DAI DAVIES

Spectacular advances in the techniques of plastic and reconstructive surgery mean that surgeons can now reposition amputated limbs and restore function to lacerated hands; they also play a vital part in multidisciplinary teams treating patients with head and neck cancer. With improved illustrations to show the surgical procedures used and the results that can be achieved, it includes chapters on the whole range of reconstructive problems from burns to malignancies.

Price: £9.00; USA\$15.00

ABC OF POISONING JOHN HENRY GLYN VOLANS **Part I – Drugs**

In this first part of a comprehensive manual the authors and their colleagues deal mainly with poisoning from drugs, but also discuss the management of poisoning in general, giving practical information on diagnosis, laboratory tests, means of elimination, and a complete up to date list of all drugs used in the treatment of poisoning.

Price: £8.50; USA\$11.50

ABC OF DIABETES PETER J WATKINS

Innovations in the treatment of diabetes have increased rapidly in the last decade: self measurement of blood glucose, intravenous infusions and intramuscular insulin for diabetic emergencies, continuous subcutaneous insulin infusions, and light coagulation for diabetic retinopathy have all helped to improve the outlook for diabetics. Dr Peter Watkins' articles provide a practical guide to the management of diabetes for the non-specialist.

Price: £6.50; USA\$11.50

STATISTICS AT SQUARE ONE T D V SWINSCOW

The statistical testing of data is indispensable in many types of medical investigation. This book provides step-by-step instruction. Subjects covered include standard deviation, χ^2 tests, t tests, non-parametric tests, Fisher's exact probability test, and rank correlation.

Price: £4.50; USA\$8.00

All prices include air mail postage. Payment must be enclosed with order. BMA members may deduct 50p or \$1.00 from the full price, quoting membership number.

For a complete catalogue of books published by the BMJ, please write to the London address.



BOOKS FROM THE BMJ

Order from The Publishing Manager, British Medical Journal, BMA House, Tavistock Square, London, England WC1H 9JR or any leading bookseller. USA, Canada & Mexico. Orders for all titles should be sent to: Taylor and Francis Inc., 242 Cherry Street, Philadelphia, PA 19106, USA.

THE CARDIOPROTECTIVE CORONARY THERAPEUTIC AGENT ADALAT.

THE MODERN COMPREHENSIVE DRUG THERAPY OF CORONARY HEART DISEASE.

Composition: 1 capsule of Adalat contains 10 mg of nifedipine. **Indications:** 1. Coronary heart disease: Chronic stable angina pectoris, angina at rest, including vasospastic angina pectoris (Prinzmetal's angina, variant angina) and unstable angina (crescendo pre-infarction angina), post-infarction angina (except for the first 8 days following the acute event). 2. Hypertension. **Contraindications:** Adalat must not be used at any time during pregnancy. No findings are as yet available as regards its use during the nursing period. Caution should be exercised if blood pressure is extremely low (severe hypotension: SBP < 90 mmHg). Cardiovascular shock. **Side effects:** Adverse reactions occur predominantly at the beginning of treatment and are often mild and transient: facial flush, heat sensation, headache. In isolated cases after high doses: nausea, dizziness, fatigue, skin reactions, paraesthesia. Hypotensive reaction, palpitations and rise in pulse rate. Occasionally leg oedemas may occur as a result of vasodilation. Very rare: Gingival hyperplasia may develop during prolonged treatment, however, this is completely reversible after medication has been stopped; chest pain (possibly angina pectoris-like symptoms). In this case nifedipine should be discontinued, if a causal relationship is suspected. Caution must be exercised in patients who have to undergo regular dialysis and suffer from malignant hypertension and in irreversible renal failure associated with hypovolaemia, since blood pressure may fall as a result of vasodilation. Antihypertensive treatment with this drug requires regular medical check-ups. The response to drug intake may in individual cases be such that the ability to drive or operate machinery is impaired. These reactions are especially pronounced at the start of treatment and in the case of a change in medication and, moreover, if alcohol is consumed at the same time. **Interactions with other drugs:** Nifedipine/antihypertensives: Concomitant use may intensify the blood pressure-lowering effect of nifedipine. Nifedipine/beta-receptor blockers: Concomitant use requires careful monitoring of the patient, since the hypotensive effect may be enhanced; moreover, the development of heart failure has occasionally been reported. Nifedipine/cimetidine: The blood pressure-lowering effect may be intensified. **Presentation:** Adalat: Packages containing 30, 50 and 100 capsules of 10 mg of nifedipine. Co-No.: 1a. Bayer, Germany.



Bayer